Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.65 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083195 | 0.91 | ESR1 (0.54) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL17083204 | 0.83 | ESR1 (0.64) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL16982202 | 0.83 | ESR1 (0.74) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL83629 | 0.82 | ESR1 (0.43) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL17083194 | 0.81 | ESR1 (0.40) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3926652 | 0.79 | ESR2 (1.00) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL1815385 | 0.79 | ESR1 (0.67) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL17083196 | 0.78 | PDE3B (0.39) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL20202922 | 0.78 | HSD17B1 (0.38) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3933773 | 0.78 | ESR2 (0.89) | ESR1ESR2HSD17B1HSD17B2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | TNK1, CTNND1, FLI1 | ESR1 2506/4885ESR2 3203/4885HSD17B1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.